Skip to main content

Table 7 Lack of change in plasma AUCs (μM.h) of PR-104, PR-104A and metabolites with repeat dosing of PR-104 at 675 mg/m2 on cycle 1 day 1 (C1D1), cycle 1 day 8 (C1D8) and cycle 2 day 1 (C2D1)

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Patient Cycle PR-104 PR-104A PR-104G PR-104H PR-104M PR-104S1
04-75 C1D1 6.34 12.11 6.60 0.51 0.06 0.16
  C1D8 6.61 13.16 7.74 0.44 0.09 0.16
01-76 C1D1 6.76 14.14 21.38 0.56 0.11 0.87
  C1D8 7.91 16.72 28.01 0.45 0.10 1.09
04-77 C1D1 14.55 17.81 7.07 0.25 0.12 0.31
  C1D8 11.01 16.96 7.53 0.26 0.12 0.36
  C2D1* 8.16 19.53 6.73 0.59 0.10 0.44
  1. *, given with naproxen.